ROIV Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of 10.54%. Roivant Sciences's return on equity of 93.1% beat AstraZeneca PLC's return on equity of 16.72%.

Roivant Sciences has a consensus price target of $16.07, signalling upside risk potential of 37.48%. On the other hand AstraZeneca PLC has an analysts' consensus of $90.46 which suggests that it could grow by 32.85%. Given that Roivant Sciences has higher upside potential than AstraZeneca PLC, analysts believe Roivant Sciences is more attractive than AstraZeneca PLC.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.454%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AstraZeneca PLC offers a yield of 2.24% to investors and pays a quarterly dividend of $0.50 per share. Roivant Sciences pays -- of its earnings as a dividend. AstraZeneca PLC pays out 75.25% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roivant Sciences quarterly revenues are $4.5M, which are smaller than AstraZeneca PLC quarterly revenues of $13.6B. Roivant Sciences's net income of -$230.2M is lower than AstraZeneca PLC's net income of $1.4B. Notably, Roivant Sciences's price-to-earnings ratio is 2.07x while AstraZeneca PLC's PE ratio is 31.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 74.71x versus 4.04x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of --. Roivant Sciences's return on equity of 93.1% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Roivant Sciences has a consensus price target of $16.07, signalling upside risk potential of 37.48%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 299.36%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Roivant Sciences, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Roivant Sciences.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $4.5M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Roivant Sciences's net income of -$230.2M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Roivant Sciences's price-to-earnings ratio is 2.07x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 74.71x versus 4.06x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Centessa Pharmaceuticals PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of --. Roivant Sciences's return on equity of 93.1% beat Centessa Pharmaceuticals PLC's return on equity of --.

Roivant Sciences has a consensus price target of $16.07, signalling upside risk potential of 37.48%. On the other hand Centessa Pharmaceuticals PLC has an analysts' consensus of $28.57 which suggests that it could grow by 67.97%. Given that Centessa Pharmaceuticals PLC has higher upside potential than Roivant Sciences, analysts believe Centessa Pharmaceuticals PLC is more attractive than Roivant Sciences.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Centessa Pharmaceuticals PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centessa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. Centessa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $4.5M, which are larger than Centessa Pharmaceuticals PLC quarterly revenues of --. Roivant Sciences's net income of -$230.2M is lower than Centessa Pharmaceuticals PLC's net income of -$42.6M. Notably, Roivant Sciences's price-to-earnings ratio is 2.07x while Centessa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 74.71x versus -- for Centessa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -5143.78% compared to Roivant Sciences's net margin of -763.91%. Roivant Sciences's return on equity of 93.1% beat Verona Pharma PLC's return on equity of -74.15%.

Roivant Sciences has a consensus price target of $16.07, signalling upside risk potential of 37.48%. On the other hand Verona Pharma PLC has an analysts' consensus of $47.29 which suggests that it could grow by 1.49%. Given that Roivant Sciences has higher upside potential than Verona Pharma PLC, analysts believe Roivant Sciences is more attractive than Verona Pharma PLC.

Roivant Sciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.012%.

Roivant Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Roivant Sciences quarterly revenues are $4.5M, which are smaller than Verona Pharma PLC quarterly revenues of $5.6M. Roivant Sciences's net income of -$230.2M is lower than Verona Pharma PLC's net income of -$43M. Notably, Roivant Sciences's price-to-earnings ratio is 2.07x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences is 74.71x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.